Christina Theodore‐Oklota

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

Karl Insogna, Karine Briot, Erik A. Imel et al. · Journal of Bone and Mineral Research · 2018 · 340 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey

Alison Skrinar, Melita Dvorak-Ewell, Ayla Evins et al. · Journal of the Endocrine Society · 2019 · 206 citations · Full text

Medicine, Child Health, Pediatrics +17

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Anthony A. Portale, Thomas O. Carpenter, Maria Luisa Brandi et al. · Calcified Tissue International · 2019 · 160 citations · Full text

Medicine, Nephrology, Pharmacotherapy +17

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma

Roger Henriksson, Andrew Bottomley, Timothy F. Cloughesy et al. · Journal of Clinical Oncology · 2015 · 138 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

The Development and Psychometric Evaluation of the Emotional Reactivity and Numbing Scale

Susan M. Orsillo, Christina Theodore‐Oklota, Jane A. Luterek et al. · The Journal of Nervous and Mental Disease · 2007 · 54 citations

Medicine, Psychiatry, Psychology +16